| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Ligand Pharmaceuticals Inc (LGND) has 11 insiders with recent SEC Form 4 filings, including 5 buys and 5 sells. LGND is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 161.3K | $35.72M | - | |
| Dir | 44.0K | $9.74M | - | |
| Dir | 33.8K | $7.48M | - | |
| Dir | 32.8K | $7.25M | - | |
| Other | 30.8K | $6.82M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 20, 2019 | Aryeh Jason | Director | Buy | 250 | $112.01 | $28,002.50 | +0.4% | |
| May 14, 2019 | Kozarich John W61 | Director | Sale+OE | 2,500 | $112.92 | $282,300.00 | -8.9% | |
| May 14, 2019 | Aryeh Jason | Director | Buy | 250 | $112.51 | $28,127.50 | +0.4% | |
| May 14, 2019 | Higgins John L66 | Chief Executive Officer | Buy | 2,500 | $113.50 | $283,750.00 | +1.8% | |
| Mar 13, 2019 | Aryeh Jason | Director | Buy | 202 | $112.51 | $22,727.02 | +0.4% | |
| Mar 13, 2019 | Higgins John L66 | Chief Executive Officer | Buy | 2,500 | $114.29 | $285,725.00 | +1.8% | |
| Oct 8, 2018 | Davis Todd C77 | Director | Sell | 2,500 | $253.99 | $634,978.00 | -5.5% | |
| Oct 1, 2018 | Kozarich John W61 | Director | Sell | 2,500 | $275.04 | $687,610.00 | -8.7% | |
| Oct 1, 2018 | Foehr Matthew W72 | President And COO | Sale+OE | 12,000 | $273.88 | $3,286,560.00 | -10.2% | |
| Sep 25, 2018 | Ligand Pharmaceuticals Inc | 10% Owner | Sell | 262,881 | $19.15 | $5,034,250.01 | -4.2% |